The successful targeting of different malignancies by OSU-2S, encouraged us to design and synthesize a novel series of pyrrolidine aryl carboxamide derivatives. In this context, we found that, the amide nature and tether length were found to be key determinant elements for the anticancer activity of these new and rigid analogues of OSU-2S. The most effective analogues induced apoptosis in cancer cells by a similar mechanism to that of OSU-2S, possibly via the activation of PKCδ in addition to their ability to induce cell cycle arrest and inhibition of cancer cell migration. Compound 10m, possesses anticancer potency comparable to that of OSU-2S when tested against cancer cell lines under study, and was found to be safer on normal cells. Furthermore, compound 10m, was found to be about 2-folds more potent than the anticancer drug Sorafenib in hepatocellular carcinoma (HCC). The newly developed compounds represent a therapeutically promising approach for the treatment of HCC.

OSU-2S成功靶向不同的恶性肿瘤，鼓励我们设计和合成一系列新颖的吡咯烷芳基羧酰胺衍生物。在这种情况下，我们发现，酰胺性质和系链长度是OSU-2S这些新的和刚性的类似物的抗癌活性的关键决定因素。最有效的类似物通过与OSU-2S类似的机制诱导癌细胞的凋亡，除了它们具有诱导细胞周期停滞和抑制癌细胞迁移的能力外，还可能通过PKCδ的激活。当针对正在研究的癌细胞系进行测试时，化合物10m具有与OSU-2S相当的抗癌能力，并且发现对正常细胞更安全。此外，复合在肝细胞癌（HCC）中，发现10m的效力比抗癌药物索拉非尼强2倍。新开发的化合物代表了治疗HCC的治疗方法。